AU Patent

AU2024205867A1 — Capsid inhibitors for the prevention of HIV

Assigned to Gilead Sciences Inc · Expires 2024-09-12 · 2y expired

What this patent protects

Provided herein are methods for preventing, or reducing the risk of acquiring, HIV using compounds of Formula la or Formula lb.

USPTO Abstract

Provided herein are methods for preventing, or reducing the risk of acquiring, HIV using compounds of Formula la or Formula lb.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: AU2024205867A1
Jurisdiction: AU
Classification: —
Expires: 2024-09-12
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.